A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.
Yara RodríguezKenji UnnoMihai Ioan TruicaZachary R ChalmersYoung A YooRajita VatapalliVinay SagarJindan YuBarbara LysyMaha HussainHuiying HanSarki A AbdulkadirPublished in: Cancer research (2022)
PRRX2 mediates enzalutamide resistance via activation of the E2F and BCL2 pathways, which can be targeted with CDK4/6 and BCL2 inhibitors to reverse resistance.